Cost Effectiveness Analysis of imatinib mesylate for the treatment of patients with unresectable and/or metastic gastro-intestinal stromal tumours

Jayne Wilson; Martin Connock; F Song; Guiqing Yao

Cost Effectiveness Analysis of imatinib mesylate for the treatment of patients with unresectable and/or metastic gastro-intestinal stromal tumours

Jayne Wilson, Martin Connock, F Song, Guiqing Yao

Cancer and Genomic Sciences

Research output: Contribution to journal › Article

Original language	English
Journal	Health Technology Assessment
Volume	9
Issue number	25
Publication status	Published - 1 Jan 2005

Cite this

@article{4b6028091124440f9d36b0ce708c7d38,

title = "Cost Effectiveness Analysis of imatinib mesylate for the treatment of patients with unresectable and/or metastic gastro-intestinal stromal tumours",

author = "Jayne Wilson and Martin Connock and F Song and Guiqing Yao",

year = "2005",

month = jan,

day = "1",

language = "English",

volume = "9",

journal = "Health Technology Assessment",

issn = "2046-4924",

publisher = "NIHR Health Technology Assessment Programme",

number = "25",

}

TY - JOUR

T1 - Cost Effectiveness Analysis of imatinib mesylate for the treatment of patients with unresectable and/or metastic gastro-intestinal stromal tumours

AU - Wilson, Jayne

AU - Connock, Martin

AU - Song, F

AU - Yao, Guiqing

PY - 2005/1/1

Y1 - 2005/1/1

M3 - Article

SN - 2046-4924

VL - 9

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 25

ER -